<DOC>
	<DOCNO>NCT01434472</DOCNO>
	<brief_summary>This phase II trial study side effect well high-dose yttrium-90 ( Y-90 ) -ibritumomab tiuxetan ( anti-cluster differentiation [ CD ] 20 ) follow fludarabine phosphate , low-dose total body irradiation ( TBI ) , donor peripheral blood stem cell transplant ( PBSCT ) work treat patient aggressive B-cell lymphoma return period improvement ( relapse ) respond previous treatment ( refractory ) . Radiolabeled monoclonal antibody , Y-90-ibritumomab tiuxetan , find cancer cell carry cancer-killing substance less effect normal cell . Giving chemotherapy , fludarabine phosphate , TBI donor PBSCT help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . However , high-dose radiolabeled antibody also destroy healthy blood cell patient 's body . When healthy stem cell donor infused patient ( stem cell transplant ) , may help patient 's body replace blood cell . Giving high-dose Y-90-ibritumomab tiuxetan follow fludarabine phosphate , TBI , donor PBSCT may effective treatment patient B-cell lymphoma .</brief_summary>
	<brief_title>High-Dose Y-90-Ibritumomab Tiuxetan Added Reduced-Intensity Allogeneic Stem Cell Transplant Regimen Relapsed Refractory Aggressive B-Cell Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess safety efficacy 1.5 mCi/kg ( max 120 mCi ) 90Y-Ibritumomab tiuxetan ( yttrium Y 90 ibritumomab tiuxetan ) ( anti-CD20 ) combine fludarabine ( fludarabine phosphate ) ( 30 mg/m^2 x 3 ) 2 gray ( Gy ) total body irradiation follow human leukocyte antigen ( HLA ) match allogeneic hematopoietic transplantation patient relapse refractory aggressive B-cell lymphoma . OUTLINE : Patients receive dosimetry test dose indium In 111 ibritumomab tiuxetan intravenously ( IV ) 10 minute within four week prior transplant receive therapy-dose high-dose yttrium Y 90 ibritumomab tiuxetan IV 30 minute day -14 prior transplant . Both ibritumomab tiuxetan infusion may precede rituximab IV , depend result blood test determine rituximab concentration . Patients receive fludarabine phosphate IV day -4 -2 undergo TBI follow allogeneic PBSCT day 0 . Patients also receive cyclosporine orally ( PO ) twice daily ( BID ) day -3 56 taper day 180 ( relate donor ) -3 100 taper 11 week ( unrelated donor ) mycophenolate mofetil PO BID day 0-27 ( relate donor ) PO thrice daily ( TID ) day 0-40 taper day 96 ( unrelated donor ) . After completion study treatment assessment ~day 100 follow transplant , patient follow 1 , 3 , 6 , 12 month annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must histologically confirm diagnosis aggressive Bcell lymphoma ( diffuse large Bcell lymphoma [ DLBCL ] , Burkitt lymphoma [ BL ] , etc . ) express CD20 antigen fail least one prior standard systemic therapy Patients must relapse highdose therapy autologous transplantation ineligible highdose therapy autologous transplantation ; patient fail autologous transplantation persistent disease &gt; 30 day transplant ; ineligible autologous transplant include chemoresistant disease ( i.e. , patient achieve partial response well recent chemotherapy regimen ) , expect poor outcome autologous transplant ( e.g. , DLBCL relapse within one year rituximab , cyclophosphamide , doxorubicin hydrochloride , vincristine sulfate , prednisone [ RCHOP ] like chemotherapy , double hit lymphoma , vmyc myelocytomatosis viral oncogene homolog ( avian ) positive [ MYC+ ] lymphoma , persistent positron emission tomography [ PET ] positivity chemotherapy ) , unable collect sufficient tumorfree autologous stem cell per Seattle Cancer Care Alliance ( SCCA ) standard practice , unable tolerate highdose autologous conditioning regimen , refuse highdose autologous transplant regimen Creatinine ( Cr ) &lt; 2.0 Bilirubin &lt; 1.5 mg/dL exception patient think Gilbert 's syndrome , may total bilirubin 1.5 mg/dL Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &lt; 3 x upper limit normal ( ULN ) Patients must expect survival without treatment &gt; 60 day must free major infection include human immunodeficiency virus ( HIV ) Patients must HLAidentical relate HLAmatched unrelated donor Systemic antilymphoma therapy give within 30 day prior therapeutic 90Yibritumomab tiuxetan dose Inability understand give inform consent Active central nervous system lymphoma Pregnancy Fertile men woman unwilling use contraceptive technique 12 month follow treatment Southwest Oncology Group ( SWOG ) /Eastern Cooperative Oncology Group ( ECOG ) performance score &gt; = 2 Highdose chemotherapy external beam radiation therapy lung , liver , kidneys &gt; 20 Gy within previous 100 day prior therapeutic 90Yibritumomab tiuxetan dose Medical condition would contraindicate allogeneic transplantation per standard practice guideline ( e.g. , impaired cardiopulmonary function , hepatitis , etc ) Altered biodistribution ( determine follow tracelabeled 111Inibritumomab tiuxetan dose )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>